PD23-06 ROGNOSTIC VALUE OF SERUM CYFRA 21-1 IN PATIENTS WITH T1G3 OR MUSCLE INVASIVE BLADDER CANCER
نویسندگان
چکیده
منابع مشابه
CYFRA 21-1 serum analysis in patients with esophageal cancer.
This study was conducted to determine a potential use of CYFRA 21-1 in patients suffering from carcinoma of the esophagus. CYFRA 21-1 serum concentrations of 50 patients with histologically proven malignant lesion of the esophagus were compared with 50 healthy persons, 50 patients with benign esophageal disease, and 50 patients with benign lung disease. Additional analysis of serum carcinoembry...
متن کاملPrognostic value of serum cytokeratin 19 fragments (Cyfra 21-1) in patients with non-small cell lung cancer
The role of serum CYFRA 21-1 level in patients with non-small cell lung cancer (NSCLC) remains to be defined. To re-evaluate the impact of serum CYFRA 21-1 in NSCLC survival, we performed this meta-analysis. Databases were searched to identify relevant studies reported after the publication of a meta-analysis in 2004. Totally, 31 studies with 6394 patients were included in this meta-analysis. T...
متن کاملUrine CYFRA 21-1 in the diagnostics of bladder cancer patients
Cystoscopy and cytology are the standard modalities used to diagnose and early detect persistent or recurrent bladder cancer. One of the possibilities of improvement in the diagnosis of bladder cancer was the introduction of assessment of tumor markers, especially evaluated in urine. The results of the recent studies on CYFRA 21-1, soluble cytokeratin 19 fragments, indicated that it is one of t...
متن کاملSerum Levels of Cyfra 21 in Patients with Benign and Malignant Salivary Gland Tumors
Introduction: Cyfra 21 is a serum-soluble fragment of cytokeratin19. Increased Cyfra 21 serum levels and their benefit as a tumor marker have been shown in some malignancies. This study aimed to evaluate the serum levels of Cyfra 21 in patients with benign and malignant salivary gland tumors. Materials and Methods: In this cross-sectional study, the serum level of Cyfra 21 in 44 patients with m...
متن کاملPrognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer.
OBJECTIVE To assess the value of Cyfra 21-1, carcino-embryonic antigen (CEA) and neuron-specific enolase (NSE) combined, all three together as prognostic factors in advanced stage non-small cell lung cancer (NSCLC) patients. PATIENTS AND METHODS Serum samples from untreated NSCLC patients were prospectively collected. All assays were performed using commercial kits blind to clinical informati...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Urology
سال: 2015
ISSN: 0022-5347,1527-3792
DOI: 10.1016/j.juro.2015.02.1422